The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Zacks.com on MSN2d
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
Cigna (CI) and UnitedHealth (UNH) significantly marked up prices for specialty generic drugs over a six-year period.
Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback